StockNews.AI
RPRX
StockNews.AI
5 hrs

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

1. Royalty Pharma will participate in a fireside chat on September 23, 2025. 2. The event will be accessible via their 'Events' webpage. 3. Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation. 4. Their portfolio includes over 35 commercial products and 17 development-stage candidates. 5. The company collaborates with various biopharmaceutical innovators.

4m saved
Insight
Article

FAQ

Why Neutral?

The fireside chat may not significantly alter market perceptions, similar past events.

How important is it?

While informative, the event does not present major new developments or announcements.

Why Short Term?

The impacts from the chat may be temporary, typically fading post-event.

Related Companies

VRTXJNJGSKRHHBYSNYABBVPFEBGNE
September 19, 2025 16:25 ET  | Source: Royalty Pharma plc NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications +1 (212) 883-6637ir@royaltypharma.com

Related News